PL2529739T3 - Therapeutic or prophylactic agent for biliary diseases - Google Patents
Therapeutic or prophylactic agent for biliary diseasesInfo
- Publication number
- PL2529739T3 PL2529739T3 PL11737151.8T PL11737151T PL2529739T3 PL 2529739 T3 PL2529739 T3 PL 2529739T3 PL 11737151 T PL11737151 T PL 11737151T PL 2529739 T3 PL2529739 T3 PL 2529739T3
- Authority
- PL
- Poland
- Prior art keywords
- therapeutic
- prophylactic agent
- biliary diseases
- biliary
- diseases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000069 prophylactic effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010018730 | 2010-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2529739T3 true PL2529739T3 (en) | 2016-12-30 |
Family
ID=44319422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11737151.8T PL2529739T3 (en) | 2010-01-29 | 2011-01-28 | Therapeutic or prophylactic agent for biliary diseases |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10131672B2 (en) |
| EP (1) | EP2529739B1 (en) |
| JP (1) | JP5867081B2 (en) |
| KR (1) | KR101732042B1 (en) |
| CN (1) | CN102711759B (en) |
| AU (1) | AU2011211223B2 (en) |
| BR (1) | BR112012018765B1 (en) |
| CA (1) | CA2787323C (en) |
| ES (1) | ES2582628T3 (en) |
| MX (1) | MX362830B (en) |
| MY (1) | MY173491A (en) |
| PH (1) | PH12012501552A1 (en) |
| PL (1) | PL2529739T3 (en) |
| RU (1) | RU2554857C2 (en) |
| TW (1) | TWI477505B (en) |
| WO (1) | WO2011093441A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012054566A2 (en) * | 2010-10-19 | 2012-04-26 | Memorial Sloan-Kettering Cancer Center | 6-amido derivatives of 4,5a-epoxymorphinans for treatment of pain |
| CA2825165C (en) | 2011-01-31 | 2018-07-03 | Toray Industries, Inc. | Therapeutic or prophylactic agent for cachexia |
| EP4212532A3 (en) | 2015-04-30 | 2023-09-27 | Memorial Sloan Kettering Cancer Center | Mitragynine analogs and uses thereof |
| CN106110220B (en) * | 2016-08-22 | 2020-01-07 | 陕西盘龙药业集团股份有限公司 | Preparation process of Chinese patent medicine for treating biliary tract diseases |
| DK3761982T3 (en) | 2018-03-08 | 2025-01-02 | Victoria Link Ltd | USE OF NALFURAFINE IN THE TREATMENT OF DEMYELINATING DISEASES |
| IL318587A (en) | 2018-07-23 | 2025-03-01 | Trevi Therapeutics Inc | Treatment of chronic cough, breathlessness and dyspnea |
| WO2020205735A1 (en) * | 2019-03-29 | 2020-10-08 | Humanwell Pharmaceutical US | Novel morphinans useful for treating medical disorders |
| IL294601A (en) | 2020-01-10 | 2022-09-01 | Trevi Therapeutics Inc | Methods of administering nalbuphine |
| US20240300939A1 (en) | 2021-06-14 | 2024-09-12 | Scorpion Therapeutics, Inc. | Urea derivatives which can be used to treat cancer |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946848A (en) * | 1985-10-29 | 1990-08-07 | Baker Cumins Dermatologicals, Inc. | Method of treating pruritus with nalmefene and clonidine |
| JP3130935B2 (en) * | 1991-06-24 | 2001-01-31 | ゼネカ リミテッド | Pharmaceutical composition |
| ES2121988T3 (en) | 1992-01-23 | 1998-12-16 | Toray Industries | DERIVATIVE OF MORFINANO AND MEDICINAL USE. |
| CN1111900A (en) | 1993-06-30 | 1995-11-15 | 东丽株式会社 | Antitussive |
| KR100341950B1 (en) | 1993-07-19 | 2002-11-29 | 도레이 가부시끼가이샤 | Brain cell protection agent |
| HU224914B1 (en) * | 1994-05-31 | 2006-04-28 | Mallinckrodt Chemical Inc | Process for the preparation of nalbuphine having not more then 1% levels of beta-epimer |
| DE69732868T2 (en) * | 1996-11-25 | 2006-04-13 | Toray Industries, Inc. | Remedy for itching |
| WO1999005146A1 (en) | 1997-07-25 | 1999-02-04 | Toray Industries, Inc. | Hyponatremia remedies |
| JP4359711B2 (en) | 1997-09-02 | 2009-11-04 | 東レ株式会社 | Drug addiction treatment |
| JP2000053572A (en) | 1998-08-11 | 2000-02-22 | Toray Ind Inc | ORL1 (opioid orphan) receptor antagonist |
| CN1204139C (en) | 1999-08-24 | 2005-06-01 | 东丽株式会社 | Remedies for neuropathic pain and model animals of neuropathic pain |
| JP2001163784A (en) | 1999-12-06 | 2001-06-19 | Toray Ind Inc | Antipruritic for cornea or conjunctiva |
| US8338442B2 (en) | 2001-03-30 | 2012-12-25 | Toray Industries, Inc. | Remedies for psychoneurosis |
| JP4239592B2 (en) | 2001-05-08 | 2009-03-18 | 東レ株式会社 | Sepsis treatment |
| US20030054030A1 (en) * | 2001-09-13 | 2003-03-20 | Gary Gordon | Method and compositions for the treatment of pruritus |
| DE10161963A1 (en) * | 2001-12-17 | 2003-07-03 | Johannes Schuetz | 6-aminomorphine derivatives, production process therefor and their use |
| US6852713B2 (en) | 2003-04-16 | 2005-02-08 | Adolor Corporation | Lactam derivatives and methods of their use |
| US6992193B2 (en) | 2003-06-10 | 2006-01-31 | Adolor Corporation | Sulfonylamino phenylacetamide derivatives and methods of their use |
| US7034051B2 (en) | 2003-08-28 | 2006-04-25 | Adolor Corporation | Fused bicyclic carboxamide derivatives and methods of their use |
| US7160902B2 (en) | 2003-11-14 | 2007-01-09 | Adolor Corporation | Amide derivatives and methods of their use |
| AU2006221314B2 (en) | 2005-03-10 | 2012-09-06 | Toray Industries, Inc. | Antipruritic agent for pruritus caused by multiple sclerosis |
| PL2151240T3 (en) * | 2007-04-24 | 2014-01-31 | Toray Industries | Therapeutic or prophylactic agent for dyskinesia |
| EP2168580B1 (en) | 2007-06-22 | 2015-12-02 | Toray Industries, Inc. | Remedy or preventive for schizophrenia |
| PL2196206T3 (en) * | 2007-10-05 | 2020-02-28 | Toray Industries, Inc. | Remedy for relieving skin troubles comprising morphinan derivative or pharmacologically acceptable acid addition salt thereof as the active ingredient |
| ES2671897T3 (en) * | 2008-02-14 | 2018-06-11 | Alkermes, Inc. | Selective opioid compounds |
| WO2009132313A2 (en) * | 2008-04-25 | 2009-10-29 | Progenics Pharmaceuticals, Inc. | Morphinan derivatives of organic and inorganic acids |
-
2011
- 2011-01-28 PH PH1/2012/501552A patent/PH12012501552A1/en unknown
- 2011-01-28 BR BR112012018765A patent/BR112012018765B1/en active IP Right Grant
- 2011-01-28 JP JP2011505302A patent/JP5867081B2/en active Active
- 2011-01-28 WO PCT/JP2011/051737 patent/WO2011093441A1/en not_active Ceased
- 2011-01-28 PL PL11737151.8T patent/PL2529739T3/en unknown
- 2011-01-28 CA CA2787323A patent/CA2787323C/en active Active
- 2011-01-28 MY MYPI2012700506A patent/MY173491A/en unknown
- 2011-01-28 KR KR1020127022530A patent/KR101732042B1/en active Active
- 2011-01-28 MX MX2012008509A patent/MX362830B/en active IP Right Grant
- 2011-01-28 EP EP11737151.8A patent/EP2529739B1/en active Active
- 2011-01-28 AU AU2011211223A patent/AU2011211223B2/en active Active
- 2011-01-28 ES ES11737151.8T patent/ES2582628T3/en active Active
- 2011-01-28 RU RU2012136826/04A patent/RU2554857C2/en active
- 2011-01-28 TW TW100103337A patent/TWI477505B/en active
- 2011-01-28 CN CN201180007520.XA patent/CN102711759B/en active Active
- 2011-01-28 US US13/522,784 patent/US10131672B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2529739A4 (en) | 2015-03-11 |
| EP2529739A1 (en) | 2012-12-05 |
| CN102711759A (en) | 2012-10-03 |
| WO2011093441A1 (en) | 2011-08-04 |
| TW201200521A (en) | 2012-01-01 |
| US20130203797A1 (en) | 2013-08-08 |
| MX362830B (en) | 2019-02-14 |
| BR112012018765B1 (en) | 2019-09-03 |
| ES2582628T3 (en) | 2016-09-14 |
| CA2787323C (en) | 2017-08-29 |
| PH12012501552A1 (en) | 2017-04-26 |
| KR20120139713A (en) | 2012-12-27 |
| JPWO2011093441A1 (en) | 2013-06-06 |
| AU2011211223A1 (en) | 2012-09-20 |
| CA2787323A1 (en) | 2011-08-04 |
| EP2529739B1 (en) | 2016-07-13 |
| AU2011211223B2 (en) | 2014-10-23 |
| RU2554857C2 (en) | 2015-06-27 |
| KR101732042B1 (en) | 2017-05-02 |
| BR112012018765A2 (en) | 2016-05-03 |
| US10131672B2 (en) | 2018-11-20 |
| TWI477505B (en) | 2015-03-21 |
| RU2012136826A (en) | 2014-03-10 |
| MX2012008509A (en) | 2012-08-31 |
| MY173491A (en) | 2020-01-29 |
| CN102711759B (en) | 2015-05-13 |
| JP5867081B2 (en) | 2016-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201506840QA (en) | Cytotoxicity-inducing therapeutic agent | |
| GB0908957D0 (en) | Therapeutic agents | |
| IL275350B (en) | Treatment for neoplastic diseases | |
| EP2586462A4 (en) | Prophylactic or ameliorating agent for genetic diseases | |
| PL2529739T3 (en) | Therapeutic or prophylactic agent for biliary diseases | |
| IL224340A (en) | Sanitary agent | |
| PL2554541T3 (en) | Therapeutic agent or prophylactic agent for fibromyalgia | |
| IL245995B (en) | Prophylactic or therapeutic agent for fibrosis | |
| ZA201301458B (en) | Therapeutic agent for pain | |
| GB0900484D0 (en) | Therapeutic agent | |
| PL3081097T3 (en) | Composition for the treatment of infertility | |
| EP2601954A4 (en) | Therapeutic agent for disease | |
| PL2599487T3 (en) | Therapeutic agent or prophylactic agent for neuropathic pain | |
| GB201003727D0 (en) | Therapeutic agent | |
| GB201010583D0 (en) | Therapeutic agents | |
| GB201012101D0 (en) | Therapeutic agents | |
| GB201012100D0 (en) | Therapeutic agents | |
| GB201012102D0 (en) | Therapeutic agents | |
| GB201010582D0 (en) | Therapeutic agents | |
| GB201010577D0 (en) | Therapeutic agents | |
| GB201014963D0 (en) | Therapeutic agents | |
| IL222623A (en) | Compositions and kits for providing therapeutic treatment | |
| GB0902450D0 (en) | Therapeutic agents | |
| GB0903949D0 (en) | Therapeutic agents | |
| GB0907971D0 (en) | Therapeutic agents |